Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

´ã³¶¾Ï¼¼Æ÷¿¡¼­ÀÇ p53, c-erbB-2 ¹× Ki-67 ´Ü¹éÁú ¹ßÇöÀÇ ÀÓ»óÀû À¯¿ë¼º The Clinical Value of p53, c-erbB-2 and Ki- 67 Expression in Gallbladder Carcinoma

´ëÇÑ¿Ü°úÇÐȸÁö 2001³â 60±Ç 6È£ p.649 ~ 655
±è±âȯ, ÃÖ¼ºÈ£, ¾ÈâÇõ, ±èÁ¤¼ö, ÀüÇظí, ÀÌÀºÁ¤, ÀÓ±Ù¿ì,
¼Ò¼Ó »ó¼¼Á¤º¸
±è±âȯ ( Kim Kee-Hwan ) 
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ÀÇÁ¤ºÎ¼º¸ðº´¿ø ¿Ü°úÇб³½Ç

ÃÖ¼ºÈ£ ( Choi Seong-Ho ) 
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ÀÇÁ¤ºÎ¼º¸ðº´¿ø ¿Ü°úÇб³½Ç
¾ÈâÇõ ( An Chang-Hyeok ) 
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ÀÇÁ¤ºÎ¼º¸ðº´¿ø ¿Ü°úÇб³½Ç
±èÁ¤¼ö ( Kim Jeong-Soo ) 
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ÀÇÁ¤ºÎ¼º¸ðº´¿ø ¿Ü°úÇб³½Ç
ÀüÇظí ( Jeon Hae-Myung ) 
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ÀÇÁ¤ºÎ¼º¸ðº´¿ø ¿Ü°úÇб³½Ç
ÀÌÀºÁ¤ ( Lee Eun-Jung ) 
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ÀÇÁ¤ºÎ¼º¸ðº´¿ø ÀÓ»óº´¸®Çб³½Ç
ÀÓ±Ù¿ì ( Lim Keun-Woo ) 
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ÀÇÁ¤ºÎ¼º¸ðº´¿ø ¿Ü°ú

Abstract


Purpose
We evaluated the correlation between clinicopathologic features and p53, c-erbB-2 and Ki-67 protein expression in gallbladder carcinoma.
Methods
From Jan. 1994 to July 1999, thirty-four cases of gallbladder carcinoma were enrolled in this study and their clinicopathologic findings were analyzed. We performed p53, c-erbB-2, and Ki-67 immunohistochemical staining on formalin fixed, paraffin
embedded histological sections with an antibody.
Results
The rate of overexpression of p53, c-erbB-2, and Ki-67 protein in gallbladder carcinoma was 47.1%, and 70.6%, 55.9%, respectively. The five year patient survival rate was significantly correlated only with tumor stage; the rate being 64.7%
(P=0.031)
with p53-negative tumors and 59.0% (P=0.023) with c-erbB-2-positive tumors.
Conclusion
Progressively increasing incidence of p53, c- erbB-2 and Ki-67 protein overexpression was observed in gallbladder carcinoma patients. Although this study found no correlation between the molecular markers and survival, further study will be
needed
to
evaluate the significance of p53, c-erbB-2 and Ki-67 proteins as prognostic factors.

Å°¿öµå

´ã³¶¾Ï; p53; c-erbB2; Ki-67; ¸é¿ªÁ¶Á÷È­ÇÐÀû¿°»ö; Gallbladder cancer; p53; c-erbB-2; Ki-67; Immunohistochemical staining;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS